AMINOSALICYLIC ACID ( DrugBank: Aminosalicylic acid )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
96 | クローン病 | 12 |
97 | 潰瘍性大腸炎 | 76 |
96. クローン病
臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215
Showing 1 to 10 of 12 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2009-011220-62-NL (EUCTR) | 26/10/2009 | 13/07/2009 | A randomized controlled withdrawal trial in Crohn's disease patients in long-term remission on mesalazine: the CROWN study A randomized controlled withdrawal trial in Crohn's disease patients in long-term remission on mesal ... | A randomized controlled withdrawal trial in Crohn's disease patients in long-term remission on mesalazine: the CROWN study A randomized controlled withdrawal trial in Crohn's disease patients in long-term remission on mesal ... | 1. Patients with a diagnosis of quiscent (CDAI < 150) Crohn's Disease (CD) according to established clinical, endoscopic, radiological and histological criteria. 2. Patients will be aged 18 years or older. 3. Patients with mesalazine maintenance therapy > 1 year. MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease 1. Patients with a diagnosis of quiscent (CDAI < 150) Crohn's Disease (CD) according to established ... | Product Name: mesalazine INN or Proposed INN: mesalazine Other descriptive name: AMINOSALICYLIC ACID | University Medical Center Utrecht | NULL | Not Recruiting | Female: yes Male: yes | Netherlands | ||||
2 | EUCTR2008-002100-26-BE (EUCTR) | 28/01/2009 | 31/07/2008 | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ... | Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ... | Ferring Pharmaceuticals A/S | NULL | Not Recruiting | Female: yes Male: yes | 510 | France;Belgium;Denmark;Germany;United Kingdom;Sweden | |||
3 | EUCTR2008-002100-26-FR (EUCTR) | 16/01/2009 | 02/09/2008 | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ... | Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ... | Ferring Pharmaceuticals A/S | NULL | Not Recruiting | Female: yes Male: yes | 510 | Phase 3 | France;Belgium;Denmark;Germany;United Kingdom;Sweden | ||
4 | EUCTR2008-002100-26-GB (EUCTR) | 07/01/2009 | 19/08/2008 | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ... | Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ... | Ferring Pharmaceuticals A/S | NULL | Not Recruiting | Female: yes Male: yes | 510 | Germany;United Kingdom;Denmark;Belgium;France;Sweden | |||
5 | EUCTR2008-002100-26-SE (EUCTR) | 27/11/2008 | 08/08/2008 | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ... | Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ... | Ferring Pharmaceuticals A/S | NULL | Not Recruiting | Female: yes Male: yes | 510 | Germany;United Kingdom;Denmark;Belgium;France;Sweden | |||
6 | EUCTR2008-002100-26-DE (EUCTR) | 19/11/2008 | 06/03/2009 | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ... | Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ... | Ferring Pharmaceuticals A/S | NULL | Not Recruiting | Female: yes Male: yes | 510 | France;Belgium;Denmark;Germany;United Kingdom;Sweden | |||
7 | EUCTR2008-002100-26-DK (EUCTR) | 04/11/2008 | 18/08/2008 | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo - PEACE PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ... | Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ... | Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ... | Ferring Pharmaceuticals A/S | NULL | Not Recruiting | Female: yes Male: yes | 510 | Germany;United Kingdom;Belgium;Denmark;France;Sweden | |||
8 | JPRN-UMIN000004427 | 2007/06/01 | 01/11/2010 | A Prospective Randomized Open Trial to Assess the Efficiency of Infliximab for Crohn's Patients after Intestinal Resection A Prospective Randomized Open Trial to Assess the Efficiency of Infliximab for Crohn's Patients afte ... | Crohn's disease | Non-infliximab arm: Conventional medicine is administered, excluding Infliximab, Azathioprine, and 6-Mercaptopurine, to subjects during the study period (for 60 months, maximum). Infliximab arm: Infliximab is administered to subjects during the study period (for 60 months, maximum) together with other conventional medications, such as 5-aminosalicylic acid. Infliximab is administered every 8 weeks to subjects during study period after the start of protocol treatment as a rule. Immunomodulators, such as Azathioprine and 6-Mercaptopurine, are not permitted during the trial. Non-infliximab arm: Conventional medicine is administered, excluding Infliximab, Azathioprine, and 6- ... | Lower GI disease, Hyogo College of Medicine | NULL | Complete: follow-up complete | 16years-old | 65years-old | Male and Female | 30 | Phase 2,3 | Japan | |
9 | NCT00495521 (ClinicalTrials.gov) | June 2007 | 29/6/2007 | High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children High Dose Oral 4-Aminosalicylic Acid(PASER®) to Control Acute Flares of Mild to Moderate Crohn's Dis ... | A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an ... | Crohn's Disease | Drug: 4-Aminosalicylic acid extended release granules | Jacobus Pharmaceutical | NULL | Terminated | 2 Years | 18 Years | All | 2 | Phase 2 | United States;Israel |
10 | NCT00417690 (ClinicalTrials.gov) | January 2007 | 2/1/2007 | High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease High Dose Oral 4-Aminosalicylic Acid(PASER®) to Control Acute Flares of Mild to Moderate Crohn's Dis ... | A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an ... | Crohn's Disease | Drug: 4-Aminosalicylic acid;Drug: PASER placebo granules | Jacobus Pharmaceutical | NULL | Terminated | 18 Years | 65 Years | Both | 54 | Phase 2 | United States;Israel |
97. 潰瘍性大腸炎
臨床試験数 : 2,527 / 薬物数 : 1,465 - (DrugBank : 259) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202
Showing 1 to 10 of 76 diseases
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04499495 (ClinicalTrials.gov) | October 25, 2021 | 31/7/2020 | Assessment of 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea Assessment of 5-Aminosalicylic AcidPrescription Patterns and Treatment Outcomes in Patients With Ulc ... | A Retrospective Study to Assess 5-Aminosalicylic Acid Prescription Patterns and Treatment Outcomes in Patients With Ulcerative Colitis in Korea A Retrospective Study to Assess 5-Aminosalicylic AcidPrescription Patterns and Treatment Outcomes in ... | Ulcerative Colitis | Other: PENTASA (mesalamine/ 5-Aminosalicylic acid (5-ASA) | Ferring Pharmaceuticals | NULL | Recruiting | 15 Years | N/A | All | 15000 | Korea, Republic of | |
2 | NCT03980405 (ClinicalTrials.gov) | April 1, 2020 | 5/6/2019 | Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis | Combination Therapy With Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatric Ulcerative Colitis: A Single Blinded, International Randomized Controlled Trial Combination Therapy With Drug and Diet for Induction of Remission in Mild to Moderate Active Pediatr ... | Ulcerative Colitis | Dietary Supplement: Group 1- Control Diet;Dietary Supplement: Group 2- UCD Diet | Prof. Arie Levine | NULL | Recruiting | 10 Years | 19 Years | All | 62 | N/A | Israel |
3 | NCT03804931 (ClinicalTrials.gov) | January 20, 2019 | 6/1/2019 | Fecal Microbiota Transplantation for Ulcerative Colitis | Efficacy and Safety of Fecal Microbiota Transplantation for Ulcerative Colitis | Ulcerative Colitis;Fecal Microbiota Transplantation | Procedure: Fecal microbiota transplantation;Procedure: Infusion of Saline;Drug: 5-Aminosalicylic acid(5-ASA) and/or Prednisone Procedure: Fecal microbiota transplantation;Procedure: Infusion of Saline;Drug: 5-Aminosalicylic aci ... | Guangzhou First People's Hospital | NULL | Recruiting | 18 Years | 65 Years | All | 120 | Phase 2/Phase 3 | China |
4 | EUCTR2015-002557-35-BG (EUCTR) | 14/03/2017 | 06/01/2017 | A study to investigate the efficacy and safety of Mesalamine 4 g extended release granules (Sachet) for the induction of clinical and endoscopic remission in mild to moderate Ulcerative Colitis A study to investigate the efficacy and safety of Mesalamine 4 g extended release granules (Sachet) ... | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Saf ... | Active, mild to moderate ulcerative colitis MedDRA version: 20.0;Level: LLT;Classification code 10058816;Term: Colitis ulcerative acute episode;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Active, mild to moderate ulcerative colitis MedDRA version: 20.0;Level: LLT;Classification code 1005 ... | Trade Name: Pentasa Compact 4g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid [5-ASA] Trade Name: Pentasa Compact 4g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other ... | Ferring International PharmaScience Center U.S., Inc. | NULL | Not Recruiting | Female: yes Male: yes | 220 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ... | Serbia;United States;Hungary;Mexico;Canada;Belgium;Ukraine;Russian Federation;Bulgaria;Latvia;Switzerland Serbia;United States;Hungary;Mexico;Canada;Belgium;Ukraine;Russian Federation;Bulgaria;Latvia;Switze ... | ||
5 | EUCTR2015-002558-11-BG (EUCTR) | 14/03/2017 | 06/01/2017 | A study to investigate the efficacy and safety of Mesalamine 2 g extended release granules (Sachet) for maintenance of clinical and endoscopic remission in Ulcerative Colitis A study to investigate the efficacy and safety of Mesalamine 2 g extended release granules (Sachet) ... | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Saf ... | Ulcerative colitis MedDRA version: 20.0;Level: LLT;Classification code 10058816;Term: Colitis ulcerative acute episode;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Ulcerative colitis MedDRA version: 20.0;Level: LLT;Classification code 10058816;Term: Colitis ulcera ... | Trade Name: Pentasa Compact 2g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid [5-ASA] Trade Name: Pentasa Compact 2g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other ... | Ferring International PharmaScience Center U.S., Inc. | NULL | Not Recruiting | Female: yes Male: yes | 260 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ... | Serbia;United States;Hungary;Mexico;Canada;Belgium;Ukraine;Russian Federation;Bulgaria;Latvia;Switzerland Serbia;United States;Hungary;Mexico;Canada;Belgium;Ukraine;Russian Federation;Bulgaria;Latvia;Switze ... | ||
6 | EUCTR2015-002557-35-LV (EUCTR) | 01/09/2016 | 01/07/2016 | A study to investigate the efficacy and safety of Mesalamine 4 g extended release granules (Sachet) for the induction of clinical and endoscopic remission in mild to moderate Ulcerative Colitis A study to investigate the efficacy and safety of Mesalamine 4 g extended release granules (Sachet) ... | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Saf ... | Active, mild to moderate ulcerative colitis MedDRA version: 19.0;Level: LLT;Classification code 10058816;Term: Colitis ulcerative acute episode;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Active, mild to moderate ulcerative colitis MedDRA version: 19.0;Level: LLT;Classification code 1005 ... | Trade Name: Pentasa Compact 4g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid [5-ASA] Trade Name: Pentasa Compact 4g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other ... | Ferring International PharmaScience Center U.S., Inc. | NULL | Not Recruiting | Female: yes Male: yes | 220 | Phase 3 | Serbia;United States;Belarus;Ukraine;Ireland;Lithuania;Russian Federation;Switzerland;Hungary;Mexico;Canada;Belgium;Bulgaria;Latvia Serbia;United States;Belarus;Ukraine;Ireland;Lithuania;Russian Federation;Switzerland;Hungary;Mexico ... | ||
7 | EUCTR2015-002558-11-LV (EUCTR) | 01/09/2016 | 01/07/2016 | A study to investigate the efficacy and safety of Mesalamine 2 g extended release granules (Sachet) for maintenance of clinical and endoscopic remission in Ulcerative Colitis A study to investigate the efficacy and safety of Mesalamine 2 g extended release granules (Sachet) ... | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Saf ... | Ulcerative colitis MedDRA version: 19.0;Level: LLT;Classification code 10058816;Term: Colitis ulcerative acute episode;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Ulcerative colitis MedDRA version: 19.0;Level: LLT;Classification code 10058816;Term: Colitis ulcera ... | Trade Name: Pentasa Compact 2g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid [5-ASA] Trade Name: Pentasa Compact 2g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other ... | Ferring International PharmaScience Center U.S., Inc. | NULL | Not Recruiting | Female: yes Male: yes | 260 | Phase 3 | Serbia;United States;Belarus;Ukraine;Ireland;Lithuania;Russian Federation;Switzerland;Hungary;Mexico;Canada;Belgium;Bulgaria;Latvia Serbia;United States;Belarus;Ukraine;Ireland;Lithuania;Russian Federation;Switzerland;Hungary;Mexico ... | ||
8 | NCT02665845 (ClinicalTrials.gov) | June 13, 2016 | 25/1/2016 | Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis). Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative ... | Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis: A Protocol of a Multi-center Prospective Randomized Investigator Blinded Trial. Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatmen ... | Ulcerative Colitis | Drug: 5-ASA;Drug: Corticosteroids | Centre Hospitalier Universitaire de Saint Etienne | NULL | Completed | 18 Years | N/A | All | 160 | Phase 3 | France;Greece;Israel;Italy;Korea, Republic of;Serbia |
9 | EUCTR2015-002557-35-HU (EUCTR) | 09/02/2016 | 16/11/2015 | A study to investigate the efficacy and safety of Mesalamine 4 g extended release granules (Sachet) for the induction of clinical and endoscopic remission in mild to moderate Ulcerative Colitis A study to investigate the efficacy and safety of Mesalamine 4 g extended release granules (Sachet) ... | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Saf ... | Active, mild to moderate ulcerative colitis MedDRA version: 19.1;Level: LLT;Classification code 10058816;Term: Colitis ulcerative acute episode;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Active, mild to moderate ulcerative colitis MedDRA version: 19.1;Level: LLT;Classification code 1005 ... | Trade Name: Pentasa Compact 4g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid [5-ASA] Trade Name: Pentasa Compact 4g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other ... | Ferring International PharmaScience Center U.S., Inc. | NULL | Not Recruiting | Female: yes Male: yes | 220 | Phase 3 | Serbia;United States;Hungary;Mexico;Canada;Belgium;Ukraine;Russian Federation;Bulgaria;Latvia;Switzerland Serbia;United States;Hungary;Mexico;Canada;Belgium;Ukraine;Russian Federation;Bulgaria;Latvia;Switze ... | ||
10 | EUCTR2015-002558-11-HU (EUCTR) | 09/02/2016 | 16/11/2015 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Saf ... | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Saf ... | Ulcerative colitis MedDRA version: 19.1;Level: LLT;Classification code 10058816;Term: Colitis ulcerative acute episode;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Ulcerative colitis MedDRA version: 19.1;Level: LLT;Classification code 10058816;Term: Colitis ulcera ... | Trade Name: Pentasa Compact 2g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-aminosalicylic acid [5-ASA] Trade Name: Pentasa Compact 2g, granulate with prolonged release INN or Proposed INN: MESALAZINE Other ... | Ferring International PharmaScience Center U.S., Inc. | NULL | Not Recruiting | Female: yes Male: yes | 260 | Phase 3 | United States;Serbia;Hungary;Mexico;Canada;Belgium;Ukraine;Russian Federation;Bulgaria;Latvia;Switzerland United States;Serbia;Hungary;Mexico;Canada;Belgium;Ukraine;Russian Federation;Bulgaria;Latvia;Switze ... |